During the process of hematogenous metastasis, tumor cells interact with platelets and their
precursors megakaryocytes, providing a selection driver for the metastatic phenotype …

Venous thromboembolism (VTE) is a major health problem in patients with cancer. Cancer
augments thrombosis and causes cancer-associated thrombosis (CAT) and vice versa …

Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact
mechanisms for the induction of VTE remain to be fully elucidated, but it is widely …

The establishment of prothrombotic states during cancer progression is well reported but the
precise mechanisms underlying this process remain elusive. A number of studies have …

Cancer cell-derived tissue factor-positive extracellular ves... : Current Opinion in Hematology
Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and …

Microvesicles (MVs) are small membrane enclosed structures released into the extracellular
space by virtually all cell types. Their composition varies according to the cell origin and the …

Treating cancer patients with deep venous thrombosis/venous thromboembolism (DVT/VTE)
can be challenging as patients are frequently unable to receive the standard therapy of …

The activation of protease-activated receptor (PAR)-2 by factor Xa (fXa) promotes the
release of tissue factor-positive microvesicles (TF+ MV), and contributes to proliferation in …

Cancer patients have an increased risk of venous thromboembolism (VTE). The rate of VTE
varies with cancer type, with pancreatic cancer having one of the highest rates, suggesting …

Microvesicles (MVs) represent a subgroup of extracellular vesicles (EVs) emerging from
various cells by blebbing of their outer membrane. Therefore, they share features such as …